التفاصيل البيبلوغرافية
| العنوان: |
Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial. |
| المؤلفون: |
Butler, Javed, Anker, Stefan D., Siddiqi, Tariq Jamal, Coats, Andrew J. S., Dorigotti, Fabio, Filippatos, Gerasimos, Friede, Tim, Göhring, Udo-Michael, Kosiborod, Mikhail N., Lund, Lars H., Metra, Marco, Quinn, Carol Moreno, Piña, Ileana L., Pinto, Fausto J., Rossignol, Patrick, Szecsödy, Peter, Van Der Meer, Peter, Weir, Matthew, Pitt, Bertram |
| المصدر: |
European Journal of Heart Failure. Supplements; Jan2022, Vol. 24 Issue 1, p230-238, 9p |
| مصطلحات موضوعية: |
VENTRICULAR ejection fraction, RENIN-angiotensin system, ACE inhibitors, RANDOMIZED controlled trials, POLYMERS, HYPERKALEMIA, HEART failure |
| مستخلص: |
Aims In patients with current or a history of hyperkalaemia, treatment with renin-angiotensin-aldosterone system inhibitors (RAASi) is often compromised. Patiromer, a novel potassium (K+) binder, may improve serum K+ levels and adherence to RAASi. Methods The DIAMOND trial will enroll ~820 patients with heart failure with reduced ejection fraction (HFrEF; ejection fraction =40%). Patients meeting the screening criteria will enter a single-blinded run-in phase where they will be started or continued on a mineralocorticoid receptor antagonist (MRA) titrated to 50mg/day and other RAASi therapy to =50% target dose, and patiromer. Patiromer will be titrated up to a maximum three packs/day (8.4 g/pack) to achieve optimal doses of RAASi without hyperkalaemia. The run-in phase will last up to 12weeks, following which patients will undergo double-blind randomization in a 1:1 ratio to receive either continued patiromer or placebo (patiromer withdrawal). The primary endpoint is the mean difference in serum K+ from randomization between patiromer and placebo arms. Secondary endpoints will include hyperkalaemia events with K+ value >5.5 mEq/L, durable enablement of MRA at target dose, investigator-reported adverse events of hyperkalaemia, hyperkalaemia-related clinical endpoints and an overall RAASi use score (using a 0-8-point scale) comprising all-cause death, occurrence of cardiovascular hospitalization or usage of comprehensive heart failure medication. Conclusion The DIAMOND trial is designed to determine if patiromer can favourably impact K+ control in patients with HFrEF with hyperkalaemia or a history of hyperkalaemia leading to RAASi therapy compromise, and in turn improve RAASi use. [ABSTRACT FROM AUTHOR] |
|
Copyright of European Journal of Heart Failure. Supplements is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
